Where:
Wyndham Boston Beacon Hill
5 Blossom Street
Boston, MA 02114
Admission:
$2498.0
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/234426-2?pid=5248
With the US in the midst of an opioid crisis, it has never been more critical for the pharmaceutical, biotechnology and academic fields to unite in a common goal to innovate and accelerate the discovery and development of novel non-opioid therapies to treat pain.
This summit and its expert speaker faculty will update you on the latest and novel RandD efforts currently ongoing in discovery and optimization of non-opioid analgesic targets and their mechanism of action. In addition, the inaugural Non-Opioid Pain Drug Development Summit will be your dedicated platform to overcome translational challenges such as animal model predictive value, biomarker identification, and proving efficacy against placebo effect.
http://www.non-opioiddrugdevelopment.com/
September 27-28, 2018
Contact:
[email protected]
+ 1 617 455 4188
URLs:
Brochure: https://go.evvnt.com/234426-0?pid=5248
Tickets: https://go.evvnt.com/234426-1?pid=5248
Prices:
Conference + 1 Workshop Earlybird (Book by 15/06/18): USD 1798.0,
Conference + 1 Workshop (standard rate): USD 2498.0,
Conference Earlybird (Book by 15/06/18): USD 1299.0,
Conference (Standard rate): USD 1999.0,
Workshop: USD 499.0
Speakers: Mary Ann Pellymounter (NIH/NINDS/Division of Translational Research), Daniel Klamer (Anavex Life Sciences Corp.), Kerrie Brady (Centrexion Corp), Crist Frangaki (Achelios Therapeutics), Lucio Rovati (Rottapharm Biotech), Silviu Itescu (Mesoblast Ltd.)
Monday, Nov 18, 2024 goes until 11/20
Child Therapy Boston